|Written by GSCR Staff
|Wednesday, 27 August 2014 08:01
In keeping with the football theme from the Guide this week as we gear up for the start of college football this week and the NFL next week, we thought we would look at one of our biggest winners. As you know, we think the market is in for a correction and now may be the time to examine some stocks for profit taking.
Back in mid-January 2013 we featured Lannett Company, Inc. (NYSE – LCI - $39.35) in the Market Monitor at $5.61. For those who do the math, that is over a 600% gain in just under 20 months!! In actuality, the stock crossed the 51% mark right before the 4th of July earlier this summer dropping to $33.61 a few weeks later, but now back on a steady climb. The question is what to do now?
For a refresher, Lannett Company currently has and develops an oral and topical drug portfolio that includes generics related to a wide variety of ailments such as glaucoma, Parkinson’s disease, migraines, antibiotic, anesthetic, endometriosis, obesity, congestive heart failure, and pain management among other applications.
Back in April we set a price for $40 to $45 for the stock. In the micro technical level LCI is still very bullish in the short term regarding DMA, but bearish neutral to long term. There is a resistance at the $40.50 level. Additionally, the Company has begun to monetize some if its portfolio. The forward P/E of 16 is still half the trailing P/E at 36 on analysts’ consensus of an 80% growth in top line revenue in 2014 over 2013. The PEG ratio of 1.33 is also attractive.
From a numbers perspective LCI still looks fairly good. However, there have been a few hurdles thrown at the Company over recent months. First, the law firm of Lifshitz & Miller filed a class action lawsuit against Lannett with allegations of potential fixing, maintaining or controlling prices of digoxin or allocating and dividing customers or territories relating to the sale of digoxin in violation of Connecticut antitrust law. Additionally, there have been some safety concerns with digoxin the Company’s generic heart drug.
We think it is time to take some money and run here. If you cannot stomach it, sell now, but we think LCI can reach $41 again in short order before some longer term negative momentum begins.
Have a great day!
Disclosure: Goldman Small Cap Research analysts are neither long nor short these shares but may elect to purchase the stock within the next 48 hours.
This Market Monitor blog was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research, which typically highlights small cap companies, and Goldman Opportunity Research, which features micro cap companies in a sponsored research format. Thus, the Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports.
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.
ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com